Across TCGA pan-cancer cohorts, FOXP1 mass-spec protein is linked to patient survival in 1 of 34 cancer types, making it a survival-associated FOXP1 data layer compared with 16 for mass-spec protein and 9 for mutation status.
The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher FOXP1 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated FOXP1 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.
PDAC are the cancer types where FOXP1 mass-spec protein most reproducibly stratifies survival.